Skip to main content
Journal cover image

Psoralen: a narrative review of current and future therapeutic uses.

Publication ,  Journal Article
Galiatsatos, P; Maydan, DD; Macalpine, E; Schleupner, B; Aitchison, AH; Lerner, AD; Levy, B; Halthore, A; Eward, W
Published in: J Cancer Res Clin Oncol
March 15, 2024

Psoralen is a family of naturally occurring photoactive compounds found in plants that acquire potential cytotoxicity when activated by specific frequencies of electromagnetic waves. Psoralens penetrate the phospholipid cellular membranes and insert themselves between the pyrimidines of deoxyribonucleic acid (DNA). Psoralens are initially biologically inert and acquire photoreactivity when exposed to certain classes of electromagnetic radiation, such as ultraviolet light. Once activated, psoralens form mono- and di-adducts with DNA, leading to marked cell apoptosis. This apoptotic effect is more pronounced in tumor cells due to their high rate of cell division. Moreover, photoactivated psoralen can inhibit tyrosine kinase signaling and influence the immunogenic properties of cells. Thus, the cytotoxicity of photoactivated psoralen holds promising clinical applications from its immunogenic properties to potential anti-cancer treatments. This narrative review aims to provide an overview of the current understanding and research on psoralen and to explore its potential future pharmacotherapeutic benefits in specific diseases.

Duke Scholars

Published In

J Cancer Res Clin Oncol

DOI

EISSN

1432-1335

Publication Date

March 15, 2024

Volume

150

Issue

3

Start / End Page

130

Location

Germany

Related Subject Headings

  • Ultraviolet Rays
  • Oncology & Carcinogenesis
  • Humans
  • Furocoumarins
  • Ficusin
  • DNA
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Galiatsatos, P., Maydan, D. D., Macalpine, E., Schleupner, B., Aitchison, A. H., Lerner, A. D., … Eward, W. (2024). Psoralen: a narrative review of current and future therapeutic uses. J Cancer Res Clin Oncol, 150(3), 130. https://doi.org/10.1007/s00432-024-05648-y
Galiatsatos, Panagis, Daniella D. Maydan, Elle Macalpine, Beatrice Schleupner, Alexandra Hunter Aitchison, Andrew D. Lerner, Benjamin Levy, Aditya Halthore, and William Eward. “Psoralen: a narrative review of current and future therapeutic uses.J Cancer Res Clin Oncol 150, no. 3 (March 15, 2024): 130. https://doi.org/10.1007/s00432-024-05648-y.
Galiatsatos P, Maydan DD, Macalpine E, Schleupner B, Aitchison AH, Lerner AD, et al. Psoralen: a narrative review of current and future therapeutic uses. J Cancer Res Clin Oncol. 2024 Mar 15;150(3):130.
Galiatsatos, Panagis, et al. “Psoralen: a narrative review of current and future therapeutic uses.J Cancer Res Clin Oncol, vol. 150, no. 3, Mar. 2024, p. 130. Pubmed, doi:10.1007/s00432-024-05648-y.
Galiatsatos P, Maydan DD, Macalpine E, Schleupner B, Aitchison AH, Lerner AD, Levy B, Halthore A, Eward W. Psoralen: a narrative review of current and future therapeutic uses. J Cancer Res Clin Oncol. 2024 Mar 15;150(3):130.
Journal cover image

Published In

J Cancer Res Clin Oncol

DOI

EISSN

1432-1335

Publication Date

March 15, 2024

Volume

150

Issue

3

Start / End Page

130

Location

Germany

Related Subject Headings

  • Ultraviolet Rays
  • Oncology & Carcinogenesis
  • Humans
  • Furocoumarins
  • Ficusin
  • DNA
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis